Statement: the primary trial recorded more seizures than the secondary trial, despite having less than one tenth the number of patients in its total cohort.
Primary_evidence: Adverse Events 1:   Total: 2/38 (5.26%)   Febrile neutropenia 0/38 (0.00%)   Abdominal pain 1/38 (2.63%)   Skin infection 0/38 (0.00%)   Seizure 1/38 (2.63%)
Secondary_evidence: Adverse Events 1:   Total: 92/490 (18.78%)   Anaemia * 1/490 (0.20%)   Anaemia of malignant disease * 0/490 (0.00%)   Febrile neutropenia * 0/490 (0.00%)   Neutropenia * 0/490 (0.00%)   Thrombocytopenia * 4/490 (0.82%)   Angina pectoris * 0/490 (0.00%)   Atrial fibrillation * 1/490 (0.20%)   Cardiomyopathy * 1/490 (0.20%)   Coronary artery disease * 0/490 (0.00%)   Pericardial effusion * 0/490 (0.00%) Adverse Events 2:   Total: 99/488 (20.29%)   Anaemia * 1/488 (0.20%)   Anaemia of malignant disease * 1/488 (0.20%)   Febrile neutropenia * 2/488 (0.41%)   Neutropenia * 1/488 (0.20%)   Thrombocytopenia * 1/488 (0.20%)   Angina pectoris * 1/488 (0.20%)   Atrial fibrillation * 0/488 (0.00%)   Cardiomyopathy * 0/488 (0.00%)   Coronary artery disease * 1/488 (0.20%)   Pericardial effusion * 2/488 (0.41%)